Dexcom, Inc. Enters Material Definitive Agreement
Ticker: DXCM · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1093557
| Field | Detail |
|---|---|
| Company | Dexcom INC (DXCM) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
Related Tickers: DXCM
TL;DR
Dexcom just signed a big deal, details TBD.
AI Summary
On December 20, 2024, Dexcom, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, such as the counterparty or the financial terms involved.
Why It Matters
This filing indicates a significant new contract or partnership for Dexcom, which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the agreement.
Key Players & Entities
- Dexcom, Inc. (company) — Registrant
- December 20, 2024 (date) — Date of Earliest Event Reported
FAQ
What type of material definitive agreement did Dexcom, Inc. enter into?
The filing states that Dexcom, Inc. entered into a material definitive agreement on December 20, 2024, but does not specify the nature of the agreement.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the other party involved in the material definitive agreement.
What are the key financial terms or obligations associated with this agreement?
The filing does not provide any details regarding the financial terms or obligations of the material definitive agreement.
When was this material definitive agreement officially entered into?
The agreement was entered into on December 20, 2024.
Does this agreement represent an acquisition, partnership, or other significant business transaction?
The filing categorizes the event as an 'Entry into a Material Definitive Agreement' but does not specify the exact nature of the transaction.
Filing Stats: 611 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-12-23 16:05:42
Key Financial Figures
- $0.001 — ange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global
Filing Documents
- dxcm-20241220.htm (8-K) — 26KB
- dxcm-20241220_g1.jpg (GRAPHIC) — 108KB
- 0001093557-24-000197.txt ( ) — 394KB
- dxcm-20241220.xsd (EX-101.SCH) — 2KB
- dxcm-20241220_lab.xml (EX-101.LAB) — 21KB
- dxcm-20241220_pre.xml (EX-101.PRE) — 12KB
- dxcm-20241220_htm.xml (XML) — 3KB
01
ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. As previously disclosed, DexCom, Inc. (the "Company") has been involved in global patent litigation with Abbott Diabetes Care, Inc. ("Abbott") and its affiliates. Both the Company and Abbott have accused the other of infringing certain patents, and each party has filed counterclaims and actions to invalidate the other party's patents. On December 20, 2024, the Company and Abbott entered into a settlement and patent cross license agreement (the "Agreement") to resolve all outstanding patent litigation between the parties (the "Litigation"). Under the terms of the Agreement, the Company granted Abbott and its affiliates, and Abbott and its affiliates granted the Company and its affiliates, a worldwide, royalty-free, non-exclusive, fully paid-up license to certain patents and patent applications relating to analyte sensing, including to all the patents asserted in the Litigation. The Agreement does not obligate the Company or Abbott to pay any royalties or any other form of financial compensation. As part of the Agreement, each party, on behalf of itself and its affiliates, has also (i) entered into a covenant not to sue until December 20, 2034; and (ii) agreed on behalf of themselves and their affiliates to refrain from challenging the patents and patent applications licensed under the Agreement for periods of time which vary depending on the relevant patents or patent applications. The description of the Agreement contained herein is qualified in its entirety by reference to the Agreement, a copy of which will be filed as an exhibit to the Company's next annual report on Form 10-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DEXCOM, INC. By: /s/ JEREME M. SYLVAIN Jereme M. Sylvain Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) Date: December 23, 2024